menu
    • menu
    [{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Undisclosed"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Poen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Undisclosed"},{"orgOrder":0,"company":"University of the Incarnate Word","sponsor":"Guardion Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of the Incarnate Word","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of the Incarnate Word \/ Guardion Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of the Incarnate Word \/ Guardion Health Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Dorzolamide Hydrochloride

    Menu

    Dorzolamide Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JGL d.d

                            Croatia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JGL d.d

                            Croatia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laboratorios Poen

                            Argentina arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laboratorios Sophia

                            Mexico arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Laboratorios Sophia

                            Mexico arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno ...

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of the Incarnate Word

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            University of the Incarnate Word

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Guardion Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

                            Details : Dorzolamide HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2020

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Guardion Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth